Genotwin Overview
- Founded
- 2020
- Status
- Private
- Latest Deal Type
- Angel
- Latest Deal Amount
- $200K
Genotwin General Information
Description
Developer of clinical tools intended to monitor and manage the emergence and spread of pathogens. The company's platform consists of medical professionals, public health officials and researchers with powerful testing insights to diagnose, monitor and precision-treat pathogens and pathogen-based cancers, provides a single tissue test to identify thousands of microbes, including pathogenic viruses, bacteria and fungi, it can characterize the complex multi-microbial environment, including communal bacteria, to infer health-associated microbiome signatures, enabling public health officials to address and control the emergence of novel pathogens at an early stage.
Contact Information
Primary Industry
Monitoring Equipment
Other Industries
Other Healthcare Services
Primary Office
- 38 Clarence Avenue
- Bridgewater, MA 02324
- United States
+1 (347) 000-0000
Genotwin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Angel (individual) | 15-Dec-2020 | $200K | 00000 | Completed | Generating Revenue |
Genotwin Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Oliver Elliott | Chief Executive Officer, President, Secretary & Board Member | ||
| Reuben Danzing | Chief Financial Officer |
Genotwin Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Raul Rabadan | Genotwin | Board Member | 000 0000 |
| Seunghee Ham | Genotwin | Board Member | 000 0000 |